Amy Zhou

882 total citations
24 papers, 529 citations indexed

About

Amy Zhou is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Amy Zhou has authored 24 papers receiving a total of 529 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 12 papers in Genetics and 5 papers in Molecular Biology. Recurrent topics in Amy Zhou's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), Acute Myeloid Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (4 papers). Amy Zhou is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), Acute Myeloid Leukemia Research (10 papers) and Eosinophilic Disorders and Syndromes (4 papers). Amy Zhou collaborates with scholars based in United States, Australia and Israel. Amy Zhou's co-authors include Stephen T. Oh, Jared S. Fowles, Elizabeth K. Engle, Olga Malkova, Cathrine A. Miner, Joan How, Shovik Bandyopadhyay, Daniel A.C. Fisher, J W Murphy and Sze Choong Wong and has published in prestigious journals such as Blood, PLoS ONE and CHEST Journal.

In The Last Decade

Amy Zhou

23 papers receiving 525 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Zhou United States 11 269 235 200 118 89 24 529
Leonardo Campiotti Italy 12 174 0.6× 155 0.7× 95 0.5× 89 0.8× 52 0.6× 22 443
Simona Pagliuca France 14 168 0.6× 314 1.3× 125 0.6× 89 0.8× 29 0.3× 69 594
Hyeoung Joon Kim South Korea 11 145 0.5× 263 1.1× 118 0.6× 47 0.4× 38 0.4× 57 471
Filiz Şen United States 16 163 0.6× 117 0.5× 112 0.6× 33 0.3× 28 0.3× 42 623
Leopold Öhler Austria 13 106 0.4× 198 0.8× 101 0.5× 32 0.3× 32 0.4× 49 478
In Keun Choi South Korea 14 79 0.3× 98 0.4× 101 0.5× 26 0.2× 83 0.9× 36 420
Kristen Pettit United States 12 187 0.7× 320 1.4× 221 1.1× 56 0.5× 8 0.1× 66 550
Mario Annunziata Italy 17 255 0.9× 592 2.5× 202 1.0× 108 0.9× 19 0.2× 51 776
Lorenza Torti Italy 10 301 1.1× 211 0.9× 192 1.0× 99 0.8× 12 0.1× 18 402
Entezam Sahovic United States 12 115 0.4× 339 1.4× 157 0.8× 17 0.1× 86 1.0× 30 613

Countries citing papers authored by Amy Zhou

Since Specialization
Citations

This map shows the geographic impact of Amy Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Zhou more than expected).

Fields of papers citing papers by Amy Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Zhou. The network helps show where Amy Zhou may publish in the future.

Co-authorship network of co-authors of Amy Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Zhou. A scholar is included among the top collaborators of Amy Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Zhou. Amy Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kong, Tim, et al.. (2024). A phase I trial of pevonedistat in combination with ruxolitinib for the treatment of myelofibrosis. Therapeutic Advances in Hematology. 15. 1574155367–1574155367. 1 indexed citations
3.
Fowles, Jared S., et al.. (2021). Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms. Frontiers in Immunology. 12. 683401–683401. 68 indexed citations
4.
Henry, David H., John A. Glaspy, Rosemary Harrup, et al.. (2021). Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study. American Journal of Hematology. 97(2). 174–184. 42 indexed citations
5.
Henry, David H., John A. Glaspy, Rosemary Harrup, et al.. (2020). Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin Levels. Blood. 136(Supplement 1). 29–30. 4 indexed citations
6.
Fowles, Jared S., Daniel A.C. Fisher, Amy Zhou, & Stephen T. Oh. (2019). Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry. Blood. 134(Supplement_1). 4210–4210. 2 indexed citations
7.
Henry, David H., John A. Glaspy, Rosemary Harrup, et al.. (2019). Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB). Blood. 134(Supplement_1). 843–843. 16 indexed citations
8.
Fisher, Daniel A.C., Cathrine A. Miner, Elizabeth K. Engle, et al.. (2019). Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. Leukemia. 33(8). 1978–1995. 93 indexed citations
9.
Zhou, Amy, Holly M. Holmes, Arti Hurria, & Tanya M. Wildes. (2018). An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All?. Drugs & Aging. 35(5). 459–465. 5 indexed citations
10.
11.
Trikalinos, Nikolaos A., Amy Zhou, Maria B. Majella Doyle, et al.. (2018). Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. Journal of the National Comprehensive Cancer Network. 16(10). 1193–1199. 46 indexed citations
12.
Bandyopadhyay, Shovik, Junjie Li, Elie Traer, et al.. (2017). Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS ONE. 12(7). e0179558–e0179558. 46 indexed citations
13.
Zhou, Amy, et al.. (2017). Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature. Current Hematologic Malignancy Reports. 12(5). 397–405. 6 indexed citations
14.
Fisher, D., Olga Malkova, Elizabeth K. Engle, et al.. (2016). Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia. 31(9). 1962–1974. 70 indexed citations
15.
Zhou, Amy, Manik Amin, Kathryn J. Fowler, et al.. (2015). Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma. Journal of the National Comprehensive Cancer Network. 13(12). 1468–1473. 9 indexed citations
16.
Zhou, Amy, Rohtesh S. Mehta, & Roy E. Smith. (2014). Outcomes of platelet transfusion in patients with thrombotic thrombocytopenic purpura: a retrospective case series study. Annals of Hematology. 94(3). 467–472. 10 indexed citations
17.
Zhou, Amy & Stephen T. Oh. (2014). Prognostication in MF: From CBC to cytogenetics to molecular markers. Best Practice & Research Clinical Haematology. 27(2). 155–164. 8 indexed citations
18.
Rodríguez‐Torres, M., Albrecht Stoehr, Edward Gane, et al.. (2013). Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis. Clinical Gastroenterology and Hepatology. 12(6). 1029–1037.e5. 21 indexed citations
19.
Kumar, Rohit, Rohtesh S. Mehta, Amy Zhou, & Roy E. Smith. (2013). Outcomes Of Platelet Transfusion In Heparin Induced Thrombocytopenia Patients. Blood. 122(21). 2311–2311. 1 indexed citations
20.
Zhou, Amy, Anne Winkler, Amir Emamifar, et al.. (2012). Is the Incidence of Heparin-Induced Thrombocytopenia Affected by the Increased Use of Heparin for VTE Prophylaxis?. CHEST Journal. 142(5). 1175–1178. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonardo Campiotti Breakdown of academic impact, for papers by Simona Pagliuca Breakdown of academic impact, for papers by Hyeoung Joon Kim Breakdown of academic impact, for papers by Filiz Şen Breakdown of academic impact, for papers by Leopold Öhler Breakdown of academic impact, for papers by In Keun Choi Breakdown of academic impact, for papers by Kristen Pettit Breakdown of academic impact, for papers by Mario Annunziata Breakdown of academic impact, for papers by Lorenza Torti Breakdown of academic impact, for papers by Entezam Sahovic
Rankless by CCL
2026